An invited Guest Editorial entitled “Give Cas a Chance,” by Fyodor Urnov, PhD, Director of Technology & Translation at the ...

Early study data from Wave Life Sciences suggests how editing RNA may yield viable medicines. Large and small drugmakers say ...

Take a bite out of our new issue, where we examine Africa’s forgotten crops and the secrets of fresh food.

Editas, one of the oldest CRISPR-focused biotechs, is pivoting again — to a sickle cell treatment that requires editing a ...

An editorial by Fyodor Urnov lays out the urgent case for major reform in the regulatory appraisal of clinical therapies involving CRISPR gene therapies.

Given this risk, we thought we'd take a look at whether CRISPR Therapeutics (NASDAQ:CRSP) shareholders should be worried ...

Editas Medicine (EDIT – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Jack Allen ...

CRISPR technology allows for precise DNA modifications, holding promise for treating genetic disorders and revolutionizing ...

EDT Cathie Wood’s ARK Investment bought 47.8K shares of Crispr Therapeutics (CRSP) today Published first on TheFly – the ...

In a potential advance for melanoma patients, researchers at ChristianaCare's Gene Editing Institute have used CRISPR gene ...

New gene therapies developed using CRISPR gene editing offer the promise of treating or even curing debilitating diseases.